Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Accumulated Expenses (2016 - 2021)

Sunshine Biopharma filings provide 8 years of Accumulated Expenses readings, the most recent being $48287.0 for Q4 2021.

  • On a quarterly basis, Accumulated Expenses rose 213.71% to $48287.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $48287.0, a 213.71% increase, with the full-year FY2021 number at $48287.0, up 213.71% from a year prior.
  • Accumulated Expenses hit $48287.0 in Q4 2021 for Sunshine Biopharma, down from $84945.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $84945.0 in Q3 2021 to a low of $1171.0 in Q1 2017.
  • Median Accumulated Expenses over the past 5 years was $28407.5 (2018), compared with a mean of $29464.0.
  • Biggest five-year swings in Accumulated Expenses: plummeted 67.11% in 2017 and later skyrocketed 1772.25% in 2018.
  • Sunshine Biopharma's Accumulated Expenses stood at $9215.0 in 2017, then rose by 0.82% to $9291.0 in 2018, then surged by 66.92% to $15509.0 in 2019, then decreased by 0.75% to $15392.0 in 2020, then surged by 213.71% to $48287.0 in 2021.
  • The last three reported values for Accumulated Expenses were $48287.0 (Q4 2021), $84945.0 (Q3 2021), and $58712.0 (Q2 2021) per Business Quant data.